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Abstract
Background: Endothelium has a function to regulate vascular tone by releasing mediators either vasodilating or
vasoconstricting blood vessels. Endothelial dysfunction can be measured conveniently by Reactive Hyperemia
Index (RHI) with a peripheral arterial tonometry. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin
II (AT II) receptor blockers (ARBs) are considered to have beneficial effects on endothelium through inhibition of
AT II. This study was performed to compare the effect of ACEIs or ARBs on endothelial function estimated by RHI in
hypertensive patients.
Methods: Twenty consecutive patients with hypertension (57.9 ± 11.3 years, 60% men) were assigned to receive
treatment with ramipril or telmisartan for eight weeks (n = 10 per group). Blood pressure (BP) and RHI were measured
at baseline and after eight weeks treatment.
Results: The two groups were similar in terms of demographic and laboratory characteristics. But baseline systolic BP
and pulse pressure (PP) were higher in telmisartan group than ramipril group (systolic BP, 159 ± 6.83 vs 150
± 7.49, p = 0.028; PP, 75.0 ± 14.0 vs 60.3 ± 12.4, p = 0.034). In both groups, systolic and diastolic BP decreased
significantly after eight weeks treatment (p < 0.05 for each). Although PP reduced in both group (ramipril
group, 60.3 ± 12.4 mm Hg to 50.4 ± 7.60 mm Hg; telmisartan group, 75.0 ± 14.0 mm Hg to 57.4 ± 15.1 mm Hg), change
was statistically remarkable only in telmisartan group. During eight weeks, there was no significant changes of RHI
in both groups. There was a positive relationship between decrease of PP after 8 weeks and the improvement of
endothelial function only in ramipril group, but not in telmisartan group (ramipril group, r = 0.671, p = 0.034; telmisartan
group, r = −0.487, p = 0.153).
Conclusions: Despite PP reduction effect favoring endothelial function, it’s not correlated with RHI improvement with
telmisartan. These findings suggest telmisartan itself may negatively influence endothelium dependent vasodilatation
different from ramipril.
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Background
Vascular endothelium is a layer of cells lining the inner
surface of vessels, separating the vascular wall from the
blood [1]. Endothelium is a paracrine, endocrine and
autocrine organ that is essential for vascular homeostasis
and regulation of vascular tone [1]. Endothelium has a
function to regulate vascular tone by release of vasodila-
tor and vasoconstrictor substance [2]. Healthy endothe-
lium has inhibitory effects on platelet aggregation and
adhesion, smooth muscle cell proliferation and leukocyte
adhesion [3].
An imbalance between endothelium derived relaxing
factor and endothelin yields vascular tone dysfunction
[2]. Endothelial dysfunction is an initiating event in ath-
erosclerotic process and leads to plaque vulnerability,
plaque rupture and thrombus formation [3, 4]. Thus the
presence of endothelial dysfunction is a predictor of
future cardiovascular events [5].
Endothelial function can be measured by Reactive
Hyperemia Index (RHI) with a peripheral arterial to-
nometry (PAT) and flow medicated dilatation (FMD) of
brachial artery with brachial artery ultrasound scanning
(BAUS) [6, 7]. Both PAT and BAUS are validated method
for evaluating peripheral endothelial function. Especially
PAT is operator non-dependent, the most convenient
and non-invasive method. The value of PAT has been
validated in many clinical studies [7, 8]. Many studies
have investigated the effect of AT II receptor blockers
(ARBs) on endothelial function assessed by FMD. In a
meta-analysis showed that ARBs improved the endothe-
lial function compared with other antihypertensive
agents and there was no difference between ARBs and
angiotensin-converting enzyme inhibitors (ACEIs) [9].
Angiotensin II (AT II) regulates endothelial function
and promotes endothelial cell apoptosis via reactive oxy-
gen species (ROS) and oxidized low-density lipoprotein
(oxLDL) uptake [10]. In many studies, ACEIs and ARBs
have beneficial effects on endothelium through inhib-
ition of AT II [3, 10]. Especially, ACEIs could improve
vasodilation via decreased levels of AT II, increased
levels of nitric oxide (NO) and bradykinin, whereas
ARBs does not elevate bradykinin level [3]. In one aspect
where ARBs can block AT II action of, ARBs seems
better in protecting endothelial function. In the other
aspect where ACE can booster bradykinin-NO path-
way, ACEIs might be better for endothelial health
(Fig. 1) [11].
However, comparison of endothelial function improve-
ment between ACEIs and ARBs has not been well stud-
ied. This study was performed to compare the effect of
ACEIs or ARBs on peripheral endothelial function esti-
mated with RHI in hypertensive patients.
Methods
Study population
This single center study was performed at Boramae
Medical Center (Seoul, Korea). From January 2014 to
February 2016, a total of 24 consecutive subjects with
essential hypertension, aged between 35 and 80 years
were enrolled. Additional inclusion criteria were: pa-
tients already receiving hypertensive therapy or previous
untreated hypertension patients. Hypertension was de-
fined as systolic blood pressure (BP) ≥140 mm Hg or
diastolic BP ≥90 mm Hg or daytime systolic BP
≥135 mm Hg or daytime diastolic BP ≥85 mm Hg at
24 h BP monitoring or nighttime systolic BP ≥125 mm Hg
or nighttime diastolic BP ≥75 mm Hg at 24 h BP
monitoring.
Subjects with following conditions were excluded: 1)
patients of serum creatinine ≥1.5 mg/dL or during
renal replacement therapy, 2) decompensated congest-
ive heart failure, 3) systolic BP >180 mm Hg and
diastolic BP >110 mm Hg, 4) acute coronary syn-
drome, 5) atrial fibrillation, 6) patients already receiv-
ing three-hypertensive therapy; high risk for the
development of hypertensive catastrophe by cessation
of medication 7) during pregnancy or planned for
pregnancy subjects.
Fig. 1 Angiotensin and kinin cascades affecting nitric oxide production ARB angiotensin II receptor blocker, AT1 angiotensin type 1, AT2
angiotensin type 2, tPA tissue plasminogen activator
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The participants were randomly assigned in a 1:1 ratio
to ramipril group or telmisartan group according to a ran-
dom number, generated by a web based randomization
program of Medical Research Collaboration Center
(MRCC) web site (https://mrcc.snuh.org/) of our institute.
The number of study patients was decided to be 24 based
on the size of research fund granted by the Korean Society
of Hypertension. Patients were assigned to receive rami-
pril 5 mg once a day or telmisartan 40 mg once a day ini-
tially. Patients already taking antihypertensive treatment
discontinued previous medications during two weeks for
washout. Follow-up visits occurred at four weeks and
eight weeks. If BP does not reach the target BP at four
weeks, upward double dose titration of drugs was pre-
scribed to reach the target BP of less than both <140 mm
Hg systolic BP and <90 mm Hg diastolic BP. And medica-
tion switched from ramipril to telmisartan, when patients
complained of ACEIs induced cough.
Data were collected at three time point: Baseline (BP,
PTA, inflammatory marker, lipid panel, renal panel,
HbA1c and fasting serum glucose), first follow-up visit
at four weeks (BP and renal panel), second follow-up
visit at eight weeks (BP, PTA, inflammatory marker, lipid
panel, renal panel, HbA1c and fasting serum glucose).
The study protocol was approved by the Boramae
Medical Center Human Research Ethics Committee.
The protocol of this study was approved by the Institu-
tional Review Board of Boramae Medical Center. And
the trial was undertaken in accordance with the Declar-
ation of Helsinki. Written informed consent was
obtained from each patient at enrollment.
Methods for endothelial function measurement
All patients in each group underwent endothelial
function test with PAT before the treatment and after
8 weeks treatment, respectively. The PAT (Endo-
PAT2000; Itamar Medical Ltd., Caesarea, Israel) was
used for non-invasive measurement of endothelial
function. This system is a noninvasive technology that
capture a beat-to-beat plethysmographic recording of
the finger arterial pulse wave analysis (PWA) with
pneumatic probes [7]. PWA was performed in accord-
ance with a protocol that described by Bonetti PO
[4]. Caffeine and alcohol are not allowed before PWA
measurement. Each subject rested at sitting position more
than 20 min in a quiet and thermoneutral (21 °C-24 °C)
room when patients exposed cold or warm temperature
before testing. Pneumatic BP cuffs were wrapped on study
arm, while the other arm determined as control arm. The
PAT finger probes were placed on the index finger of both
hands. The reactive hyperemia procedure includes five
minutes baseline recording, five minutes of blood flow
occlusion through BP cuff inflation above systolic pressure
and five minutes of recording after cuff deflation (Fig. 2).
RHI was calculated from the ratio of the average
PWA during post-occlusive period compared with the
average PWA during pre-occlusion baseline period.
The ratio was normalized to the ratio from contralat-
eral arm. Reproducibility of PAT was previously
described by Bonetti PO [4].
Statistical analysis
All numeric data are expressed as mean ± standard devi-
ation for continuous variables or percentage for discrete
variables. The differences in clinical characteristics and
RHI were compared using the Wilcoxon-Mann–Whit-
ney test for continuous variable and Chi-square test and
Fisher’s exact test for discrete variables. Univariate asso-
ciations between RHI and systolic BP, diastolic BP, pulse
pressure (PP) and laboratory findings including lipid
Fig. 2 A representative reactive hyperemia arterial tonometry recording of a subject with normal reactive hyperemia index
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profile, HbA1c and inflammatory marker were evalu-
ated using Pearson’s bivariate correlation analysis.
Scatter plots were used to show the association be-
tween the 2 continuous parameters. The significance
systolic BP, diastolic BP, PP and RHI changes were
examined with Wilcoxon signed-rank tests for each
group. A P value of <0.05 is used to indicate statis-
tical significance. All statistical tests were performed
with SPSS for Windows version 22 (IBM Co.,
Armonk, NY, USA).
Results
Twenty-four Eligible patients were randomized from
January, 2014 to February, 2016. Of the 24 patients who
entered the study, 4 patients were excluded from the
analysis due to follow up loss. Therefore a total of 20
patients (83.3%) entered the analysis. There were 12
male and 8 female, ranging from 37 to 75 years in age.
20 consecutive patients were assigned to receive treat-
ment with ramipril or telmisartan (n = 10 per group).
Baseline characteristics of this study population are
shown in Table 1. The two groups were similar in
terms of demographic and baseline laboratory charac-
teristics. But baseline systolic BP and PP were higher
in telmisartan group than ramipril group (systolic BP,
159 ± 6.83 vs 151 ± 7.49, p = 0.028; PP, 75.0 ± 14.0 vs
60.3 ± 12.4, p = 0.034).
Figure 3 and Table 2 show BP, PP and their changes
during the study period. In both groups, systolic and dia-
stolic BP decreased significantly after 8 weeks treatment.
The systolic BP ranged from 140 to 170 mm Hg and the
diastolic BP ranged from 60 to 115 mm Hg at baseline.
The BP was 151 ± 7/91 ± 9 mm Hg in the ramipril group
and 159 ± 7/84 ± 14 mm Hg in the telmisartan group at
baseline. At 8 weeks follow up, BP was 130 ± 7/80 ±
5 mm Hg in ramipril group and 131 ± 14/73 ± 9 mm Hg
in telmisartan group. BP reduction from baseline to the
8 weeks follow up was 21/11 mm Hg (systole/diastole)
in the ramipril group and 28/11 mm Hg (systole/dia-
stole) telmisartan group, respectively (p value, Wilcoxon
signed-rank test : 0.005, 0.012, 0.005, 0.036, respectively).
The target BP (<140 mm Hg systolic and <90 mm Hg
diastolic) was achieved in 9 (90%) patients in the rami-
pril group and 6 (60%) in the telmisartan group at
8 weeks follow up. PP reduced in both group (ramipril
group, 60 ± 12 mm Hg to 50 ± 8 mm Hg; telmisartan
group, 75 ± 14 mm Hg to 57 ± 15 mm Hg). But, change
was statistically remarkable in telmisartan group, while it
was borderline significant in ramipril group (p = 0.066,
Wilcoxon signed-rank test).
Table 3 and Fig. 3 demonstrate the baseline and
8 weeks follow up RHI of both groups. The baseline
RHI was 1.94 ± 0.28 in ramipril group and 1.80 ± 0.26
with telmisartan group (p = 0.272). At 8 weeks follow up,






Age, years 57.9 ± 11.3 55.9 ± 11.2 59.8 ± 11.7 0.449
Male, n (%) 12 (60%) 8 (80%) 4 (40%) 0.17
Traditional risk factors
Diabetes mellitus, n (%) 5 (25%) 2 (20%) 3 (30%) 1.0
Current smoking, n (%) 5 (25%) 4 (40%) 1 (10%) 0.303
Systolic blood pressure, mmHg 155 ± 8.04 151 ± 7.49 159 ± 6.83 0.028
Diastolic blood pressure, mmHg 87.2 ± 12.0 90.6 ± 9.00 83.7 ± 14.0 0.08
Pulse pressure, mmHg 67.7 ± 14.9 60.3 ± 12.4 75.0 ± 14.0 0.034
Mean blood pressure, mmHg 110 ± 8.25 111 ± 6.21 109 ± 10.1 0.518
Major laboratory findings
Fasting blood glucose, mg/dL 119 ± 44.2 104 ± 9.86 128 ± 55.1 0.77
HbA1c, % 5.93 ± 0.68 5.70 ± 0.62 6.6 0.18
Total cholesterol, mg/dL 185 ± 40.0 186 ± 43.2 184 ± 40.1 0.954
HDL cholesterol, mg/dL 47.7 ± 9.26 47.3 ± 9.37 48 ± 10.0 0.936
LDL cholesterol, mg/dL 113 ± 32.3 104 ± 32.3 122 ± 32.7 0.423
Triglyceride, mg/dL 180 ± 101 163 ± 93.2 197 ± 114 0.521
Potassium, mmol/L 4.31 ± 0.294 4.41 ± 0.219 4.16 ± 0.344 0.135
hs-CRP, mg/dL 0.433 ± 0.825 0.085 ± 0.06 1.13 ± 1.27 0.364
Reactive hyperemia index 1.87 ± 0.273 1.94 ± 0.284 1.80 ± 0.258 0.272
HDL high-density lipoprotein, LDL low-density lipoprotein, hs-CRP high sensitive C-reactive protein
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Fig. 3 Systolic BP, diastolic BP, PP and reactive hyperemia index in patients at baseline and after 8 weeks of treatment with ramipril or telmisartan
∗ p < 0.05 vs baseline
Table 2 Blood pressure and pulse pressure before and after treatment
Parameter Systolic blood pressure Diastolic blood pressure Pulse pressure
Baseline After 8 weeks P valueb Baseline After 8 weeks P valueb Baseline After 8 weeks P valueb
Total 155 ± 8.04 130 ± 11.1 <0.001 87.2 ± 12.0 76.2 ± 7.61 0.001 67.7 ± 14.9 53.9 ± 12.2 0.001
Ramipril 5 mg group 151 ± 7.49 130 ± 7.12 0.005 90.6 ± 9.00 79.2 ± 5.25 0.012 60.3 ± 12.4 50.4 ± 7.60 0.066
Telmisartan 40 mg group 159 ± 6.83 131 ± 14.4 0.005 83.7 ± 14.0 73.1 ± 8.61 0.036 75.0 ± 14.0 57.4 ± 15.1 0.005
P valuea 0.028 0.492 0.08 0.065 0.034 0.363
aComparison between patients using ramipril and telmisartan
bComparison between before and after treatment
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the RHI was 1.64 ± 0.33 in ramipril group and 1.59 ±
0.46 in telmisartan group (p = 0.256). During 8 weeks,
there was no significant changes of RHI in both groups.
As mentioned above, the effects of 8 weeks of treat-
ment on PP were more marked and significant in telmi-
sartan group. However, despite of this favorable change
of PP, telmisartan group have shown a tendency of
discrepancy between changes of PP and RHI, although
statistically insignificant, which means aggravation of
endothelial function even with decreased PP. On the
other hand, there was a positive relationship between
decrease of PP after 8 weeks and increase of RHI in
ramipril group (ramipril group, r = 0.671, p = 0.034;
telmisartan group, r = −0.487, p = 0.153, Fig. 4).
Both medications were relatively well tolerated except
one adverse event. One patient in ramipril group experi-
enced transient global amnesia probably due to small
vessel infarction. Only one patient had to change her
medication from ramipril to telmisartan because of dry
cough caused by ramipril.
Discussions
The present study intended to investigate if ramipril and
telmisartan affect endothelial function differently from
each other after the treatment for eight weeks in hyper-
tensive patients. During short period of treatment, while
endothelial function estimated with RHI did not change
in both groups. Both agents reduced systolic and
diastolic blood pressure effectively without difference
between two groups.
But, the effects of 8 weeks of treatment on PP were
more marked and significant in telmisartan group.
Despite these favorable hemodynamic changes, telmisar-
tan didn’t show improving endothelial function.
Although mean RHI was stationary in ramipril group
during the treatment, what extent RHI changed by is
well positively correlated with changes of PP, which
means the more decrease PP, the better endothelial func-
tion. However, this correlation was not seen in telmisar-
tan group.
A few studies postulated wide PP adversely affect
endothelial function [12–15]. Because any other factors
associated with endothelial function such as lipid profile,
smoking history, were not different between groups, the
fact improvement of endothelial function is not corre-
lated with decrease of PP in telmisartan group suggests
telmisartan itself may negatively influence endothelium
dependent vasodilatation.
Ramipril, a kind of ACEIs reduces the AT II level
by inhibition of AT I converts to AT II, increases NO
and other endothelial mediators induced by bradyki-
nin via inhibition of kininase II, which is responsible
for the degradation of bradykinin [16]. Bradykinin
affects vasodilatation via NO, prostacyclin and hyper-
polarizing factor [17].
Telmisartan, a kind of ARBs inhibits the renin angio-
tensin system (RAS) in different way from ACEIs. ARBs
bind to the AT1 receptor, interrupting its activation. As
Table 3 Reactive hyperemia index before and after treatment
Baseline After 8 weeks P valueb
Total 1.87 ± 0.273 1.61 ± 0.393 0.014
Ramipril 5 mg group 1.94 ± 0.284 1.64 ± 0.331 0.083
Telmisartan 40 mg group 1.80 ± 0.258 1.59 ± 0.464 0.103
P valuea 0.272 0.256
aComparison between patients using ramipril and telmisartan
bComparison between before and after treatment
Fig. 4 Association of delta pulse pressure and delta reactive hyperemia index in total patients (left), ramipril (middle) and telmisartan (right)
group Delta reactive hyperemia index indicates RHI after 8 weeks minus RHI at baseline, and Delta PP Baseline PP minus PP after 8 weeks
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a result of AT1 receptor blockade, ARBs increase AT II
concentration by a positive feedback resulting in stimu-
lating AT II type 2 receptors (AT2Rs) as alternative
pathway. AT2Rs have a role in vasodilatation by counter-
acting AT1 receptor mediated vasoconstriction [18].
And ARBs lead to bradykinin-dependent NO release
through AT2R [19]. AT II binding to AT2Rs induces
intracellular acidification, which activates a kininogen-
ase. This increases production of bradykinin, which in-
creases NO and vascular smooth muscle cell relaxation
[10, 19]. But, many studies have demonstrated negative
effects of persistent AT2R stimulation recently. AT2Rs
mediate arterial hypertrophy, cardiac hypertrophy and
fibrosis and anti-angiogenic effect on cardiovascular
tissues, although it’s uncertain if all of these changes
accompany endothelial dysfunction [18, 20, 21].
In this respect, ‘ARB-acute myocardial infarction (MI)
paradox’ was issued in 2004 after releasing VALUE trial.
This theory focused on increase of MI in valsartan arm
compared with amlodipine arm in the VALUE trial
(hazard ratio = 1.19, 95% CI 1.02 to 1.38, p = 0.02)
[22, 23]. Other meta-analysis of ACEIs and ARBs tri-
als showed that ACEIs (versus placebo, non ARBs
comparator and ARBs) reduced the relative risk of MI
by 14% (OR 0.86, 95% CI 0.82 to 0.90, p < 0.001),
whereas ARBs (versus placebo, non ACEIs comparator
and ACEIs) increased the risk of MI (OR 1.08, 95%
CI 1.01 to 1.16, p = 0.03) [24]. Although a meta-
analysis of Tsuyuki and McDonald reported that
ARBs did not increase the risk of MI with OR of 1.03
(95% CI 0.93 to 1.13) compared to ACEIs, many sub-
sequent studies disproved the results [25]. The
BPLTTC meta-regression analysis of 26 trials (17 tri-
als with ACEIs and 9 trials with ARBs) showed that
both ACEIs and ARBs have BP dependent risk reduc-
tion of stroke, coronary heart disease and heart fail-
ure [26]. However, after adjusted for BP reduction
within trials, the estimated risk reduction for coronary
heart disease was 9% (3 to 14%, p = 0.004), whereas
ARBs do not. Furthermore, ONTARGET compared
telmisartan with ramipril in patients with vascular
disease or high risk diabetes [27]. Telmisartan bad
better BP lowering effect than ramipril, but increased
MI by 7%, although statistically insignificant.
This randomized trial showed patients in both
groups didn’t show improvement of endothelial func-
tion than baseline after 8 week treatment, even
though blood pressure reduction was enough. This
finding the improvement of endothelial function and
reduction of BP are not corresponding has ever been
reported by Ghiadoni et al. [28]. In his study, ACEIs,
calcium antagonists, ARBs, and beta blockers similarly
reduced BP, but only perindopril, one type of ACEI,
improved endothelial function.
It’s notable the reduction of PP is well correlated with
the improvement of endothelial function expressed as a
RHI not in telmisartan group, but in ramipril group.
Higher PP exerts lower shear stress against arterial wall
subsequently resulting in larger oxidative stress and
reduced NO production [13]. In telmisartan group, PP
decreased significantly after treatment. However, PP
reduction was not related with endothelial function
improvement in telmisartan group. This finding sug-
gests telmisartan is likely to have a prohibiting effect
on endothelial functional recovery initiated by PP
reduction.
Several limitations of our study should be mentioned.
First, the present study is too small study to make a con-
firmatory conclusion regarding inferiority of telmisartan
in the aspect of endothelial function. Actually, there are
many studies revealing favorable effects of ARBs on
endothelial function. Shuang Li et al. investigated 1737
patients of 22 trials with endothelial dysfunction, and
showed that ARBs could improve endothelial function
assessed by FMD compared with placebo or other
hypertensive medication such as calcium channel
blockers, beta-blockers and diuretics [9]. But, ARBs have
no significant difference with ACEIs. Other many
studies show ARBs and ACEIs improved endothelial
function without difference. Hornig et al. demon-
strated that ACEIs and ARBs improved endothelial
vasodilatation to a similar extent in coronary artery
disease patients through increasing NO availability
[29]. Second, blood flow in cutaneous vessels is
known to depend on sympathetic and autonomic ner-
vous systems. Therefore, it is possible that changes in
the finger RHI may occur due to changes in room
temperature and mental status. We attempted to con-
trol these confounders by studying in a quiet and
automatically thermostatic room and adjusting pulse
amplitude of study arm with one of the contralateral
control arm as a reference. Third, we just investigated
short term effects of ACEIs and ARBs. It should be
further evaluated the results shown in this study can
be consistent in long term aspect.
Conclusion
In hypertensive patients, ramipril and telmisartan re-
duced systolic and diastolic BP after eight weeks
treatment. But, PP lowering effect was shown statisti-
cally significant only in telmisartan group. Despite PP
lowering effect, telmisartan didn’t show endothelial
function improvement proportional to reduced PP.
These findings suggest telmisartan may negatively
influence endothelium and emphasize the role of
bradykinin mediated NO production pathway in the
control of endothelial function, which is saved with
ramipril treatment.
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